BioNTech SE has generated substantial financial support for its portfolio of personalised cancer medicines with a Series B financing of $325 million – one of the largest single private financing rounds for a European biotechnology company. The fundraising was led by Fidelity Management & Research Co with participation from both new and existing investors.
Based in Mainz, Germany BioNTech has a portfolio of messenger RNA-based product candidates, chimeric antigen receptor T cell therapies, checkpoint immunomodulators, antibodies and small molecule drugs.